Marijana Tadic
Professor in Internal Medicine and Cardiology
Charité – Universitätsmedizin Berlin
Berlin, Germany
Charité – Universitätsmedizin Berlin
Berlin, Germany
Adherence to management and treatment for CVD can be affected by a number of factors which fall into categories of patient-related, health system-related, or socio-environmentally related [Lisy, 2025]. Specific barriers within these are identified that influence treatment adherence in patients with CVD such as perceived lack of support, concerns about taking medication (drug adherence is reportedly a particular issue in hypertension management), and lack of engagement in exercise and lifestyle changes [Rashidi, 2020; Burnier, 2019]. In contrast, high rates of adherence to both therapeutic agents and lifestyle changes resulted in a meaningful decrease in CV events, hospitalizations, and mortality and to improved quality of life [Lisy, 2025]. Facilitators for adherence include nurses [Lisy, 2025; Rashidi, 2020], who can play an important role in enhancing the provision of information pre-hospital discharge and support in the community on taking medication, the value of physical activity and dietary changes as well as specific nurse-led interventions, digital tools [Bernal-Jiménez, 2021], cardiac rehabilitation programmes [Lisy, 2025], targeted dietary interventions [Chávez-Alfaro, 2025], peer-led digital health lifestyle interventions [Lim, 2025]) and increasing the patients’ perception of the value of taking their medication [Rashidi, 2020].
At the end of the activity, learners should be able to:
Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who diagnose and manage patients with CVD and hypertension.
English with simultaneous translation into Russian and Chinese
Video Interview
Adherence to lifestyle advice and treatment following CVD diagnosis
Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.
Marijana Tadic, MD, PhD is a specialist and Professor in Internal Medicine and Cardiology. She was trained in Serbia, Italy, UK, Netherlands and Germany. Her main interest is diagnosis of cardiac remodeling in broad spectrum of cardiovascular diseases using advanced imaging techniques. Prof. Tadic is the author of more than 400 research articles, editorial member of several large cardiology journals and received several important grants. She is Editor-in-Chief in Echocardiography Journal since 2024.
Stay in the know with our CME updates